- Home
- TWIN vs CHRS Comparison
TWIN vs CHRS Comparison
Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- CHRS
- Stock Information
- Founded
- TWIN 1918
- CHRS 2010
- Country
- TWIN United States
- CHRS United States
- Employees
- TWIN N/A
- CHRS N/A
- Industry
- TWIN Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWIN Industrials
- CHRS Health Care
- Exchange
- TWIN Nasdaq
- CHRS Nasdaq
- Market Cap
- TWIN 152.3M
- CHRS 191.3M
- IPO Year
- TWIN N/A
- CHRS 2014
- Fundamental
- Price
- TWIN $11.35
- CHRS $1.24
- Analyst Decision
- TWIN
- CHRS Strong Buy
- Analyst Count
- TWIN 0
- CHRS 4
- Target Price
- TWIN N/A
- CHRS $5.38
- AVG Volume (30 Days)
- TWIN 18.2K
- CHRS 2.0M
- Earning Date
- TWIN 02-05-2025
- CHRS 03-12-2025
- Dividend Yield
- TWIN 1.41%
- CHRS N/A
- EPS Growth
- TWIN N/A
- CHRS N/A
- EPS
- TWIN 0.68
- CHRS N/A
- Revenue
- TWIN $304,470,000.00
- CHRS $304,340,000.00
- Revenue This Year
- TWIN N/A
- CHRS $2.47
- Revenue Next Year
- TWIN N/A
- CHRS N/A
- P/E Ratio
- TWIN $16.74
- CHRS N/A
- Revenue Growth
- TWIN 6.98
- CHRS 44.19
- 52 Week Low
- TWIN $10.22
- CHRS $0.66
- 52 Week High
- TWIN $18.00
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- TWIN 48.13
- CHRS 37.51
- Support Level
- TWIN $11.17
- CHRS $1.38
- Resistance Level
- TWIN $11.54
- CHRS $1.45
- Average True Range (ATR)
- TWIN 0.34
- CHRS 0.13
- MACD
- TWIN 0.04
- CHRS -0.04
- Stochastic Oscillator
- TWIN 68.90
- CHRS 4.50
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.